Original ArticleShort-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants
Section snippets
Study design
This study consists of a subpopulation of the Genetics of Lipid-lowering Drugs and Diet Network (GOLDN) study. GOLDN is a National Institutes of Health–funded study consisting of families with 3-generation pedigrees observed in 2 clinical centers (Minneapolis, Minn, and Salt Lake City, Utah) with predominantly Caucasian populations of European ancestry. The primary aim of the GOLDN study is to investigate the interaction of genetic and environmental factors on individual responses to
Results
Demographic information and baseline levels of HDL-C, LDL-C, and triglycerides (TGs) of the 96 GOLDN participants are listed in Table I. Fenofibrate treatment resulted in significant increases in HDL-C (4.44 mg/dL, P < 0.0001) and LDL-C (P = 0.0475) and a significant decrease in TGs (–150.9 mg/dL, P < 0.0001).
Lp-PLA2 mass at baseline and after 3 weeks of fenofibrate treatment (160 mg/day) are shown in Figure 1, A. Data were stratified by tertiles according to baseline levels of Lp-PLA2.
Discussion
As a class of drugs, fibrates are used clinically along with diet to treat hypertriglyceridemia and are intended to reduce the risk of atherosclerosis and CVD events by lowering TGs and favorably elevating HDL-C. Although fibrates are effective in reducing TG levels, results in the literature have been inconsistent as to whether fibrate treatment decreases CVD risk. The fibrate gemfibrozil was shown to reduce CVD events significantly, although only a portion of the benefits of the drug could be
References (42)
- et al.
Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease
Atherosclerosis
(2000) - et al.
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus
J Am Coll Cardiol
(2008) - et al.
Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men
Atherosclerosis
(2007) - et al.
Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review
Mayo Clin Proc
(2007) - et al.
Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions
Biochim Biophys Acta
(1994) - et al.
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate
J Lipid Res
(2008) - et al.
Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity
Pharmacol Res
(2006) - et al.
Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels
Atherosclerosis
(2008) - et al.
Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants
Atherosclerosis
(2011) - et al.
Adhesion molecules and atherosclerosis
Atherosclerosis
(2003)
Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors
J Mol Cell Cardiol
PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells
Eur J Pharmacol
Nuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: differential requirement for PARP-1 expression and interaction
Cell Signal
Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells
Int Immunopharmacol
Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins
J Lipid Res
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor
Biochem J
Lipoprotein-associated phospholipase A(2), a marker of vascular inflammation and systemic vulnerability
Eur Heart J
with Lp-PLA(2) Studies Collaboration. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies
Lancet
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction
Vasc Health Risk Manag
Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells
J Clin Invest
Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells
J Clin Invest
Cited by (6)
Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: A systematic review of the literature
2012, AtherosclerosisCitation Excerpt :Of these studies, 20 studies only selected participants free from prevalent vascular disease or clearly increased CVD risk; 26 studies excluded participants with prevalent vascular disease but included some participants selected with clearly increased risk of CVD (e.g. presence of established CVD risk factors such as diabetics or metabolic syndrome); and 31 studies selected at least some participants based upon the presence of existing vascular disease. Levels of Lp-PLA2 activity varied considerably across studies, with large variations across a range of different assay methods (Table 1 [4,8–91]). Twenty five studies reported levels of Lp-PLA2 activity or mass in males and females separately, of which all studies involving >500 participants reported levels which were lower in females compared to males, typically by approximately 10% (Fig. 1).
Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: A narrative review
2013, Current Medical Research and Opinion
Supported by National Heart, Lung, and Blood Institute Grant U01HL072524-04.